Orbis Medicines has raised €90m ($94m) in Series A funding to advance the develo...
The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with...
Do you have a sweet tooth? If so, it may be costing you more than you think. But...
You may have heard of people losing weight by getting vitamin B12 shots or takin...
Life can sometimes feel like a rollercoaster ride—full of ups, downs, and a few ...
Orbis Medicines has raised €90m ($94m) in Series A funding to advance the develo...
The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with...
The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-1...
The transaction is expected to close in the first half of 2025, subject to the s...
Candid plans to conduct first-in-human studies in 2026 as it continues its T-cel...
Variant has entered a multi-year research partnership with Novo Nordisk to ident...
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol ...
GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adul...
Sickle cell patient advocacy groups in the US are calling for greater education ...
Recent research published in the esteemed European Heart Journal has unearthed c...
The mental health landscape for children and adolescents in the UK is increasing...
